Irish researches find potential therapy for wet AMD

Article

Scientists at Trinity College Dublin have found that a component of the immune system suppresses the production of damaging blood vessels behind the retina, which could aid in the treatment of wet age-related macular degeneration, according to research recently published in Science Translational Medicine.

Dublin, Ireland-Scientists at Trinity College Dublin have found that a component of the immune system suppresses the production of damaging blood vessels behind the retina, which could aid in the treatment of wet age-related macular degeneration, according to research recently published in Science Translational Medicine

In pre-clinical models, the component, IL-18, could be administered in a non-invasive way, which the researchers say could be a major improvement to the current therapeutic options available to AMD patients.

“We were initially concerned that IL-18 might cause damage to the sensitive cells of the retina, because it is typically linked to inflammation. But, surprisingly, we found that low doses had no adverse effects on the retina and yet still suppressed abnormal blood vessel growth,” says Sarah Doyle, assistant professor of immunology at Trinity.

Current treatment options for wet AMD include regular injections of antibiotics mad directly into the eye to prevent vascular endothelial growth factor (VEGF) toward the end stages of the disease. Researchers found that IL-18 directly inhibits VEGF production, and that it can work as effectively as the current treatment when administered via a non-invasive intravenous injection in pre-clinical settings. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Paul Karpecki, OD, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
© 2025 MJH Life Sciences

All rights reserved.